# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Charles River Laboratories International, Inc. (NYSE:CRL) and Toxys today announced a collaboration that offers Charles River...
Adhishthana.com notes Charles River Stock is nearing its Phase 18, with momentum weakening and long-term outperformance looking...
William Blair analyst Matt Larew upgrades Charles River (NYSE:CRL) from Market Perform to Outperform.
Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from ...
Barclays analyst Luke Sergott upgrades Charles River (NYSE:CRL) from Equal-Weight to Overweight and raises the price target ...
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...
Renowned investor Kevin O’Leary expressed his belief on Wednesday that owning only Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ...